Santhera's Polish Reimbursement Win Offsets Investor Jitters Over 2027 Cash Dip
Published on 10/09/2026 at 08:00 | Editorial boerse-global.de
Santhera Pharmaceuticals has secured national reimbursement for its flagship Duchenne muscular dystrophy therapy AGAMREE in Poland as of October 1, a development disclosed by the company's CFO during its half-year earnings webcast. Poland ranks as the sixth-largest DMD market in Europe by the company's own assessment, and the addition broadens the patient pool meaningfully while confirming that the drug's European rollout is proceeding on schedule.
The announcement lands against a backdrop of subdued trading. Shares of the Swiss biotech closed Wednesday at EUR 15.32, down 2.9%, and were trading 3.0% lower at EUR 15.30 on Thursday, with no fresh company-specific news driving the move. The stock now sits roughly 24% below its 52-week high, extending a soft stretch that has seen the equity shed 6.1% since the half-year results were published just over a week ago and 14.7% since a DMD study analysis on Agamree was released about a month ago.
Operating leverage takes hold
Those declines contrast with the operational picture painted by the company's first-half 2026 figures. Revenue doubled to CHF 48.3 million from CHF 24.0 million in the same period a year earlier, while the operating loss narrowed sharply to CHF 6.6 million. Product sales drove the top-line advance, and management simultaneously tightened its cost base — evidence, in the company's telling, that the business model is gaining operating leverage and edging closer to break-even.
Whether that momentum carries through the remainder of the year is now the central question for investors. Management has reaffirmed its full-year 2026 revenue guidance of CHF 80 million to CHF 90 million, a range that, as confirmed during the earnings webcast, does not yet factor in any additional revenue-linked milestone payments. Hitting the middle or upper end of that corridor would require second-half sales broadly in line with the first six months.
Should investors sell immediately? Or is it worth buying Santhera Pharmaceuticals?
Cash trajectory and the German rebate
A pair of headwinds loom over the 2027 outlook. Santhera expects its cash position to decline in the first half of 2027, citing deferred inventory orders and a mandatory price rebate in Germany that takes effect from the first quarter of that year. Through the end of 2026, however, liquidity is projected to remain largely stable.
Crucially, management sees no need for additional financing despite the anticipated 2027 cash dip — a signal that removes the dilution overhang that had weighed on sentiment. Existing shareholders, for now, face no prospect of a capital raise.
Long-range targets sharpened
Beyond the current year, Santhera has firmed up its longer-term ambitions. For 2028, the company reiterated a revenue target of approximately CHF 140 million excluding milestone payments, with that figure projected to climb to roughly CHF 250 million by 2030. The decision to keep milestone income out of the guidance reflects a deliberately conservative planning approach, anchoring forecasts in organic sales growth rather than speculative one-off payments.
Santhera Pharmaceuticals at a turning point? This analysis reveals what investors need to know now.
The geographic expansion underpins that trajectory. Reimbursement in Poland adds a sizable European market to the commercial footprint and cushions the impact of the German rebate on early-2027 expectations. For investors willing to look past the near-term noise, the combination of disciplined cost management, a broadening reimbursement map, and a financing runway that requires no fresh equity presents a growth profile that remains intact. The year-end 2026 report will serve as the next hard checkpoint, when actual revenue and the promised liquidity position can be measured against the guidance.
Ad
Santhera Pharmaceuticals Stock: New Analysis - 9 October
Fresh Santhera Pharmaceuticals information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
